Abbott (NYSE:ABT) announced today that the FDA has authorized its dual glucose-ketone sensing technology for people with diabetes. The authorization of the Libre Duo 10 Day system — which provides 10 days of wear time — comes three months after the company reported a CE mark in the EU for the Libre Duo and Libre […]
abbott
MiniMed Flex now integrated with Abbot’s Instinct sensor
MiniMed (Nasdaq: MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. The MiniMed Flex system is MiniMed’s smallest and only app-controlled insulin pump. According to the company, Instinct is the world’s smallest sensor and offers up to 15 days of wear. Powered by SmartGuard technology, MiniMed Flex automatically adjusts insulin delivery, and the Meal Detection technology can […]
Abbott, Google to deliver glucose insights through artificial intelligence
Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing glucose insights from Abbott’s Lingo biowearable will combine with Google Health’s technology to provide a more comprehensive view of people’s health. […]
The 10 largest diabetes tech companies in the world in 2026
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Abbott to launch Libre Duo dual sensor internationally in the fall, expects future reimbursement catalysts
Abbott (NYSE:ABT) plans to launch its Libre Duo dual glucose-ketone sensor internationally in the fall, company leadership said today. CEO and Chair Robert B. Ford said on the company’s second-quarter earnings call that Abbott expects the launch in a few months, following CE mark approval for the multi-analyte sensor in May. Branded as Libre Duo […]
Abbott gets FDA nod for longer length Esprit BTK drug-eluting scaffold
Abbott (NYSE:ABT) announced today that the FDA approved the longer length (76 mm) Esprit BTK drug-eluting scaffold system. The longer Esprit BTK system received approval for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). CLTI can cause extreme pain, open wounds that don’t heal and, in some cases, […]
Tandem Diabetes Care launches t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in new geographies
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it launched the t:slim X2 insulin pump with the Abbott FreeStyle Libre 3 Plus in five new countries. San Diego-based Tandem launched the pairing of its flagship automated insulin delivery system with Control-IQ+ technology with Abbott’s latest continuous glucose monitor (CGM) sensor in the U.S. in October 2025. […]
The biggest diabetes tech news out of ADA 2026
The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
Abbott studies reinforce DKA opportunity following dual sensor milestone
Abbott (NYSE:ABT) today announced new clinical data highlighting the importance of managing diabetic ketoacidosis (DKA). The medtech giant shared findings from multiple studies at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans that demonstrate sharp increases in DKA-related hospitalizations across all age groups with type 1 and type 2 diabetes nationwide. Abbott […]
